EDITION OF WED 11 NOV 2026
42 · HEALTH

FDA requires rare vision-loss warning for GLP-1 drugs

publishers 37articles 38first reported 9 Nov, 12:00 UTCdeveloping since 9 Nov · 7 editions

The U.S. Food and Drug Administration is requiring makers of GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to add warnings about a potentially increased risk of a rare eye condition that can cause permanent vision loss.

The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when reduced blood flow damages the optic nerve. Sometimes called an “eye stroke,” it can cause painless, abrupt vision loss, blurred vision, blind spots or distorted colors, often in one eye. The FDA advised patients who experience visual changes while taking a GLP-1 drug to contact a health care professional immediately.

The agency said NAION has been reported with all currently marketed GLP-1 receptor agonists. Its review included adverse-event reports and clinical studies involving more than 125,000 patients. The FDA found about six cases annually per 100,000 people taking GLP-1 drugs, compared with fewer than four per 100,000 among people receiving a placebo or other diabetes medications.

The absolute risk appears small, and whether the drugs directly cause the condition remains uncertain. Several NAION risk factors—including diabetes, cardiovascular disease, high blood pressure and sleep apnea—are also common among patients prescribed GLP-1 drugs.

Novo Nordisk said the available data do not establish a cause-and-effect relationship and that it remains confident in its medicines’ benefit-risk profile. Eli Lilly said it was reviewing the FDA update and would continue evaluating reports of eye-related events.

HOW THIS STORY WAS MADE

Written from 8 articles, 4 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 48 h after the record first saw the story; the editor kept it as written.

Publishers
37
Source articles
38
Given to the writer
8, 4 with the article's own text
Independent newsrooms
8
This version written
48 h after the record first saw the story
Second model (editor)
kept as written
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and published it as written.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

NAMED IN THE COVERAGE

OUTLETS CARRYING THE STORY, RUN BY RUN

0 21 43 10 Nov 11 Nov 12 Nov 13 Nov 14 Nov 15 Nov 10 Nov 00:23 UTC · US is requiring weight-loss drug makers to warn about possible loss of eye sight 10 Nov 06:21 UTC · US is requiring weight-loss drug makers to warn about possible loss of eye sight 10 Nov 18:23 UTC · US is requiring weight-loss drug makers to warn about possible loss of eye sight 11 Nov 18:21 UTC · FDA requires rare vision-loss warning for GLP-1 drugs

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Nothing new took hold after the first third.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →